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Abstract
Post-translational methylation of histone lysine or arginine residues plays important roles in gene regulation and
other physiological processes. Aberrant histone methylation caused by a gene mutation, translocation, or overexpression
can often lead to initiation of a disease such as cancer. Small molecule inhibitors of such histone modifying enzymes
that correct the abnormal methylation could be used as novel therapeutics for these diseases, or as chemical probes
for investigation of epigenetics. Discovery and development of histone methylation modulators are in an early stage
and undergo a rapid expansion in the past few years. A number of highly potent and selective compounds have been
reported, together with extensive preclinical studies of their biological activity. Several compounds have been in
clinical trials for safety, pharmacokinetics, and efficacy, targeting several types of cancer. This review summarizes
the biochemistry, structures, and biology of cancer-relevant histone methylation modifying enzymes, small molecule
inhibitors and their preclinical and clinical antitumor activities. Perspectives for targeting histone methylation for cancer
therapy are also discussed.
Keywords: Histone methylation, Enzyme inhibitor, Histone lysine methyltransferase, Protein arginine methyltransferase,
Histone demethylase, Cancer therapeutics
Background
Nucleosome is the smallest structural unit of the human
genetic material, which is composed of ~146 base pairs
of double-stranded DNA wrapped around a histone
octamer that contains two copies of histone H2A, H2B,
H3, and H4 proteins. Basic lysine and arginine residues
are enriched in histones. At physiological pH, these posi-
tively charged sidechains provide strong electrostatic
and H-bond interactions with the negatively charged
DNA for tight binding and packaging. Chromatin, a lin-
ear array of millions of nucleosomes, is organized into
higher orders of structure and tightly condensed to form
a chromosome. Functionally, chromatin is classified into
highly packed, transcriptionally inactive heterochromatin
and transcriptionally active euchromatin, whose struc-
ture is less condensed and DNA is therefore more
accessible to a transcription machinery [1, 2]. Post-
translational modifications of histones, such as acetyl-
ation and methylation, largely control DNA accessibility
and regulate gene expression. For example, acetylation
can neutralize the positive charged lysine sidechain and
render a more open DNA structure to facilitate the
binding of transcription factors as well as other proteins
for gene expression. Abnormal histone modifications
often occur in many diseases such as cancer. Histone
modifying enzymes are therefore potential drug targets
for these diseases [3, 4]. Small molecule inhibitors of his-
tone deacetylases (HDAC) have been extensively devel-
oped and several compounds, such as vorinostat and
romidepsin, have been approved to treat T-cell lymph-
omas [5–7]. Moreover, HDAC inhibitors have been in
many clinical trials for other hematologic and solid can-
cers, with >500 studies in clinicaltrials.gov.
Physiological and pathological functions of histone
methylation in a lysine or arginine residue have been
well studied and documented. These post-translational
modifications play crucial roles in gene regulation, cell
* Correspondence: ysong@bcm.edu
1Department of Pharmacology, Baylor College of Medicine, 1 Baylor Plaza,
Houston, TX 77030, USA
2Dan L. Duncan Cancer Center, Baylor College of Medicine, 1 Baylor Plaza,
Houston, TX 77030, USA
© 2016 Song et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Song et al. Journal of Hematology & Oncology  (2016) 9:49 
DOI 10.1186/s13045-016-0279-9
differentiation, DNA recombination, and damage repair
in normal cells as well as pathogenesis in diseases [4, 8].
A large family of ≥60 histone methyltransferases (HMT),
including histone lysine methyltransferases (HKMT) and
protein/histone arginine methyltransferases (PRMT),
were identified in humans, among which the biochem-
ical and biological functions of many methyltransferases
have been characterized [9, 10]. In addition, histone
methylation is dynamically controlled by histone/protein
lysine demethylases (KDM), enzymes that remove the
methyl group(s) from a methylated lysine sidechain [11–
13]. The opposite functions between HMTs and KDMs
facilitate to maintain balanced histone methylation levels.
Aberrant histone methylations have been frequently found
in cancer [4, 8], caused by a gene mutation, translocation,
or dysregulated expression. Therefore, many HMTs and
KDMs are potential drug targets and small molecule in-
hibitors of these proteins are useful chemical probes or
potential therapeutics. As compared to that of HDAC in-
hibitors, development of histone methylation modulators
has been in an early stage [4, 14]. There were very few
potent inhibitors of HMTs and KDMs before 2010. Sig-
nificantly more efforts from the academia and pharma-
ceutical industry have been observed during the past few
years, leading to a rapidly increased number of small mol-
ecule modulators of histone methylation [15–17]. Several
potent and selective compounds have recently been in
clinical trials against acute myeloid leukemia (AML), non-
Hodgkin lymphoma and lung cancer, showing the great
potential for this class of compounds in cancer therapy.
This review summarizes the biochemistry, structures,
and biology of histone methylation modifying enzymes,
small molecule inhibitors and their preclinical and clin-
ical antitumor activities. Due to the large number of
these proteins, only those highly relevant to cancer are
described, with a particular focus on histone H3 lysine 79
(H3K79) methyltransferase DOT1L, H3K4 targeting mixed
lineage leukemia (MLL) and lysine-specific demethylase 1
(LSD1), and H3K27 methyltransferase EZH2. We also in-
clude mutations of isocitrate dehydrogenases (IDH), which
have recently been found in 20–80 % of gliomas, AML
and several types of sarcomas. The mutant IDH proteins
indirectly inhibit a broad range of histone demethylases
and cause genome-wide histone hypermethylation. In
addition, perspectives of targeting histone methylation for
cancer therapy are discussed.
Biochemistry and structure
HMTs belong to a superfamily of methyltransferases
containing >100 members from bacteria to humans [9,
10, 18, 19]. In addition to the lysine and arginine side-
chains of a protein, methyltransferases can methylate
DNA, RNA and even small molecules such as a cat-
echolamine. The methyl acceptors for these enzymes
can be a N (e.g., –NH2 of a lysine), C (e.g., C5-cytosine
in DNA), or O (e.g., –OH of a catecholamine) atom. All
methyltransferases use S-adenosylmethionine (SAM) as
the enzyme cofactor, with its methyl group (activated by
the sulfonium) being the donor. Figure 1a schematically
illustrates the general mechanism of catalysis of an
HMT. SAM and the substrate histone lysine bind to dif-
ferent binding pockets of HMT in an orientation that
brings the methyl donor and acceptor atoms to a close
proximity, which facilitates the ensuing nucleophilic sub-
stitution reaction to occur, producing the methylated
histone and S-adenosylhomocysteine (SAH).
Based on X-ray crystallographic studies, there are five
classes of methyltransferases with distinct structural fea-
tures [9, 10]. It is of interest that H3K79 methyltransferase
DOT1L and all PRMTs belong to class I methyltransfer-
ases and share high similarities. However, all other
HKMTs are class V methyltransferases containing a SET
(Su(var)3-9, Enhancer-of-zeste, Trithorax) domain, having
a distinct structure from DOT1L. Figure 1b, c show the
overall structures as well as the close-up views of the ac-
tive sites of DOT1L and H3K9 methyltransferase G9a, re-
spectively. DOT1L is a typical class I methyltransferase
[20], characterized by an overall protein structure of 7-
stranded β sheets flanked by several α helices, as well as
an extended binding conformation of SAM (Fig. 1b). The
SAM-binding pocket is deeply buried inside the protein.
While there has been no structural information as to
how nucleosome (the substrate) binds to DOT1L, the
substrate-binding pocket is largely separated from that
of SAM, interconnected by a narrow lysine binding
channel. The class V methyltransferase G9a is a struc-
turally distinct protein, consisting of mostly β sheets
interlinked by loops (Fig. 1c) [21]. SAM/SAH adopts a
kinked binding conformation in this class of HMTs.
For the opposite reaction, there are two families of
KDMs that can oxidatively remove the methyl group from
a methylated lysine sidechain using distinct mechanisms.
LSD1 (also known as KDM1A) and its homolog LSD2
(also known as KDM1B) are flavin adenine dinucleotide
(FAD) dependent monoamine oxidases (MAO) [22, 23].
As shown in Fig. 2a, the methyl group of a methylated ly-
sine is oxidized by the cofactor FAD to form an imine
intermediate, which hydrolyzes to give the demethylated
product and formaldehyde. FADH2, the reduced form of
the cofactor, is oxidized by O2 to generate FAD and H2O2
to complete a catalytic cycle. Because the formation of an
imine intermediate is required, LSD1/2 can only demeth-
ylate a mono- or di-methylated lysine, but not a tri-
methylated lysine. Figure 2b shows the X-ray crystal struc-
ture of LSD1 in complex with FAD and its H3K4 peptide
substrate (with K4M mutation) [24]. FAD is tightly bound
inside LSD1, with its aromatic tricyclic flavin ring being
part of the large substrate-binding pocket, which can
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accommodate and recognize the histone H3 peptide. The
sidechain of Lys4 (mutated to Met) residue is located in
proximity to the flavin ring for oxidation.
The other family, consisting of ~30 KDMs including
KDM2 - 7 and PHF (plant homeodomain finger) in
humans, all contain a JmjC domain and are Fe(II) and α-
ketoglutarate (α-KG) dependent dioxygenases [13, 25, 26].
Figure 2c illustrates the general mechanism of catalysis for
these enzymes [27, 28]. An oxygen molecule coordinates
to Fe(II) and oxidizes both Fe(II) and α-KG to give (upon
decarboxylation) a succinate and Fe(IV)-oxo intermediate.
Next, the Fe(IV) species oxidizes the C atom of the meth-
ylated lysine to form a hydroxymethylamine intermediate,
which hydrolyzes to produce the demethylated product
and formaldehyde. Unlike LSD1/2, the JmjC family of
KDMs can demethylate mono-, di-, and tri-methylated ly-
sine. Figure 2d shows the X-ray structure of PHF8 in
complex with Fe2+, an α-KG analog and a methylated his-
tone H3 peptide [29]. The central metal ion is coordinated
with an Asp and two His residues, together with two O
atoms of α-KG. One of the methyl groups of H3K9me2
sidechain is located closely to the metal ion.
To date, six lysine residues in histone H3 and H4, i.e.,
H3K4, K9, K27, K36, K79, and H4K20, have been found
to be methylated. Figure 3 illustrates the substrate-
specificity of HKMs and KDMs. Many other lysine resi-
dues, including H3K14, 18, 23, and H4K5, 8, 12, and 16,
are not methylated. Rather, they can be acetylated. It is
also of interest that H3K9 and K27 can also be acety-
lated. Mutually exclusive acetylation or methylation at
H3K9 and K27 appears to play drastically distinct
physiological functions. Acetylated H3K9 and K27 cause
activated gene transcription, while methylated H3K9 and
K27 are transcriptional repressive.
Fig. 1 Mechanism and structures of histone methyltransferases (HMT). a Mechanism of catalysis for HMTs. Upon binding to a HMT, the histone
lysine NH2 group undergoes a nucleophilic attack to the methyl group of SAM, producing a methylated lysine and SAH; b The overall structure
of DOT1L-SAM complex (PDB: 1NW3) and the close-up view of its active site; c The overall structure of G9a-SAH complex (PDB: 3K5K) and the
close-up view of its active site. SAM/SAH are shown as tube models with their C atoms in green
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H3K79 methyltransferase DOT1L
DOT1L’s physiological function and pathogenesis in
leukemia
DOT1L (disruptor of telomeric silencing 1 like) was
identified as a human homolog of yeast DOT1, which
was found to disrupt telomeric silencing in budding
yeast in a genetic screen [30]. The full-length human
DOT1L has 1537 amino acids, with its highly conserved
N-terminal domain of ~360 amino acids being an
H3K79 methyltransferase [31]. The remaining part of
Fig. 2 Mechanisms and structures of histone lysine demethylases (KDM). a Mechanism of catalysis for FAD dependent KDM1 proteins (including LSD1
and 2); b The active site of LSD1 in complex with FAD and a histone H3 peptide (PDB: 2V1D). LSD1 is shown as a 50 % transparent electrostatic surface.
The peptide is shown as a wire model (C atoms in green), with the K4M residue highlighted as a tube model; c Mechanism of catalysis for JmjC
domain KDMs; d The active site of PHF8 in complex with Fe2+ (cyan sphere), an α-KG analog (brown) and a histone H3 peptide (green) (PDB: 3KV4)
Fig. 3 Histone H3 and H4 lysine substrate-specificity of HMTs and KDMs
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mammalian DOT1L is involved in interactions with
many transcription proteins, such as AF4, AF9, AF10,
and ENL [32–36]. Biology of DOT1L in health and dis-
eases has been summarized in several recent reviews
[37–39]. The biological function of DOT1L (as well as
DOT1) is to methylate H3K79 as part of a transcription
complex, which can initiate or maintain an active tran-
scription state. This is supported by the genetic studies
in yeast, showing ~10 % genome containing hypomethy-
lated H3K79 are located at transcriptionally inactive loci,
while the remaining 90 % genes with an H3K79 methyl
marker are actively transcribed [40, 41]. This also occurs
in Drosophila and mammals [42, 43]. Several large tran-
scription protein complexes containing DOT1L have been
purified and identified using chromatin immunoprecipita-
tion, including ENL-associated proteins (EAP), DOT1L-
containing complex (DotCom), and Super elongation
complex (SEC) [32–36]. Several transcription relevant
proteins were repeatedly present in these complexes, in-
cluding transcription factors AF4, AF9, AF10, and ENL, as
well as P-TEFb kinase. P-TEFb is a cyclin-dependent kin-
ase that can phosphorylates RNA polymerase II, which is
required for transcription elongation. These strongly sup-
port DOT1L as well as H3K79 methylation is crucial to
gene transcription.
DOT1L plays important roles in normal physiology of
an organism. For embryonic development, methylation
at H3K79 is absent in the very early stage and increasing
levels of H3K79me2 can be found in later stages, sug-
gesting this “histone code” is important for embryonic
development [44, 45]. Germline knockout of mouse
DOT1L was embryonic lethal and major defects in the
cardiovascular system were found in the knockout em-
bryos [46]. Additionally, DOT1L has been found to be
crucial for maintaining normal hematopoiesis in mice
[47, 48]. Conditional knockout of DOT1L in bone mar-
row significantly decreased hematopoietic stem cells as
well as all types of progenitor cells. Moreover, other
studies have shown DOT1L plays roles in maintaining
normal functions of heart and kidney [46, 49–51].
DOT1L has been found to be a drug target for acute
leukemia with a mixed lineage leukemia (MLL, also
known as MLL1 or KMT2A) gene translocation. This sub-
type of leukemia accounts for ~75 % of acute leukemia in
infants and ~10 % in children and adults [52–54] with a
particularly poor prognosis [55–58]. The phenotype of
MLL-rearranged leukemia can be acute myeloid leukemia
(AML), acute lymphoid leukemia (ALL), or mixed lineage
leukemia. However, despite phenotypic differences, gene
profiling showed these MLL-rearranged leukemias share a
similar gene expression signature [59]. The biology of
MLL and leukemogenesis of MLL-rearranged oncogenes
have been well studied and reviewed [60–62]. Briefly,
MLL is a large, multi-domain protein (3969 amino acids),
containing an N-terminal AT hook domain that recog-
nizes and binds to DNA as well as a C-terminal SET do-
main that is an H3K4 methyltransferase [52]. Figure 4a
schematically illustrates the biology of MLL for gene ex-
pression in normal cells. Upon binding to the promoter
region of its target genes, the SET domain of MLL can
Fig. 4 Functions of wild-type MLL, LSD1 and onco-MLL fusion proteins. a MLL methylates H3K4 and initiates RNA polymerase II (Pol II) mediated
gene transcription, while LSD1 removes the methyl group from H3K4me1 and 2 and keeps a balanced H3K4 methylation; b The onco-MLL protein
complex involving AF4, AF9, AF10, or ENL can recruit DOT1L, which methylates H3K79 and causes overexpression of leukemia-relevant genes
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methylate H3K4, which also represents a histone marker
for active gene transcription [63, 64]. In the leukemia, the
chromosome rearrangement replaces the C-terminal part
of MLL with a fusion partner gene [52, 53, 65]. The SET
domain as well as its H3K4 methylation activity is thus
lost. To date, although >70 partner genes have been docu-
mented, onco-MLLs fused with transcription factors AF4,
AF9, AF10, and ENL account for the majority (>70 %). As
shown in Fig. 4b, these four proteins are able to recruit
DOT1L into the MLL transcription complex, which sub-
sequently methylates H3K79 [32, 34, 51, 66, 67]. This ab-
errant epigenetic event dysregulates the expression of
many MLL target genes, such as HoxA9, HoxA7, and
Meis1 whose overexpression can cause leukemia. Abnor-
mal H3K79 methylation has been observed in the clinic as
well as mouse models of MLL-rearranged leukemia and
becomes hallmarks of this malignancy. DOT1L therefore
represents a drug target for MLL leukemias. Indeed, this
has been established by biological means (e.g., knockdown
by RNA interference) [66] and pharmacological inhibition
as described below [68–76].
DOT1L inhibitors and their activity against MLL leukemia
Because of DOT1L’s crucial role in oncogenesis and
maintenance of MLL-rearranged leukemia, much effort
has been dedicated to find small molecule inhibitors of
DOT1L. The first DOT1L inhibitor EPZ004777 (1, Fig. 5)
as well as its selective antitumor activity against MLL
leukemia were reported in 2011 [68]. Several other po-
tent DOT1L inhibitors were disclosed shortly after [69–
75]. Figure. 5 summarizes representative inhibitors of
DOT1L, as well as their biochemical and antitumor
activities. It is noted that all currently disclosed DOT1L
inhibitors contain an adenosine or its analogous struc-
ture and are competitive to the enzyme cofactor SAM.
This is likely because of the difficulty to compete with
the substrate nucleosome, which has strong protein-
protein and protein-DNA interactions with DOT1L [70].
The discovery of compound 1 followed a conventional
ligand-based medicinal chemistry approach [69]. Starting
with the natural inhibitor SAH (Ki = 260 nM), a series of
repeated cycles of chemical modifications followed by
structure activity relationship studies yielded 1, which
still has an adenosine-like moiety, while the sidechain in
SAH is replaced with a tert-butylphenyl urea containing
tertiary amine group. Compound 1 exhibited an ex-
tremely potent inhibitory activity against DOT1L with a
Ki value of 0.3 nM, ~860-fold more active than SAH. In
addition, unlike SAH being a broadly active inhibitor of
HMTs, 1 shows an excellent enzyme selectivity profile: it
did not inhibit a panel of 8 other HMTs at 50 μM, al-
though 1 is a relatively weak inhibitor of PRMT5 (IC50:
520 nM). X-ray crystallographic studies showed that the
binding of compound 1 causes large protein conform-
ational changes of DOT1L to accommodate the large
hydrophobic sidechain [69]. Surface plasmon resonance
(SPR) studies revealed that a very slow koff rate mostly
accounts for the potent inhibitory activity of compound
1. Further inhibitor optimization produced EPZ-5676 (2)
with an improved activity (Ki = 0.08 nM) as well as cellu-
lar activities [73]. Several other groups also disclosed
their DOT1L inhibitors. Structure-based design led to
the finding of compound 3, a N6-methyl substituted
SAH, which retains the inhibitory activity of SAH
Fig. 5 Structures and activities of representative DOT1L inhibitors
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against DOT1L and exhibits excellent selectivity against
other HMTs [71]. Compound 4 is a potent, mechanism-
based inhibitor of DOT1L, with the ability to covalently
bind to the substrate [71]. Compounds 5 and 6 are ana-
logs of 1 and also showed highly potent inhibition
against DOT1L (Ki = 1.1 and 0.06 nM) [75, 76]. Com-
pound 5 with a cyclopentane ring (rather than the ribose
in other compounds) was designed, synthesized and
shown to retain a potent inhibitory activity against
DOT1L. However, it exhibited a significantly improved
metabolic stability [75]. X-ray structure-based design for
compound 6 with a 7-bromo substituent on the adenine
ring was intended to exploit a nearby hydrophobic
pocket and it turned out that 6 is one of the most potent
inhibitors of DOT1L [76].
Compounds 1, 2, 5, and 6 are cell permeable and exhibit
selective activities against MLL-rearranged leukemia cells
[68, 73, 75]. It is remarkable that these DOT1L inhibitors
are not cytotoxic and did not exhibit anti-proliferative ac-
tivity for a short (e.g., 3 days) treatment. Rather, a long
time (e.g., 14 days) incubation is needed, showing a dis-
tinct mechanism of action for these compounds [69, 70].
The slow action is likely because of a long time required
for a series of cellular events that arrest cell growth, in-
cluding H3K79 methylation inhibition, followed by sys-
tematic changes of gene expression. Compound 1 only
inhibited cellular H3K79 methylation with an IC50 of ~50
nM and did not affect other histone methylations signifi-
cantly. 1 inhibited the proliferation of MLL-rearranged
leukemia cells with EC50 values of 0.17–6.5 μM, while it
showed significantly reduced activity against leukemia
cells without a MLL rearrangement (EC50: 13.9–>50 μM).
Treatment with 1 caused downregulation of onco-MLL
target genes and induced cell differentiation as well as
apoptosis of MLL-rearranged leukemia cells. Gene profil-
ing also revealed that there were significant overlaps in
gene expression pattern between samples treated with
compound 1 and DOT1L knockdown, supporting DOT1L
is the cellular drug target. Due to the poor pharmacokin-
etics, continuous infusion using an osmotic pump was
chosen for administration of compound 1 for in vivo
studies. A dose of 70 mg/kg for 21 days was able to
cause a regression of subcutaneous tumors of MV4-11
leukemia cells. In a more clinically relevant systemic
MV4-11 leukemia mouse model, compound 1 can also
prolong survival of the experimental animals with stat-
istical significance.
Compound 2 is the most potent DOT1L inhibitor, to-
gether with improved pharmacokinetics [73]. It showed
more potent cellular activities (e.g., EC50s = 0.004–1.5 μM)
and in vivo antitumor efficacy. It has been in phase I clin-
ical trials against MLL-rearranged leukemia. Preliminary
clinical results of compound 2 were disclosed in the 56th
Annual Meeting of American Society of Hematology [77]
as well as several press releases (www.epizyme.com). A
total of 37 advanced leukemia patients, who were heavily
pretreated with chemotherapies, were enrolled and re-
ceived 6 doses (ranging from 12 to 90 mg/m2/day for 21
or 28 days) of continuous infusion of 2. The compound
was well tolerated, with the main adverse events being
grade 1 or 2 leukocytosis, nausea and hypomagnesemia.
Drug administration can achieve a rapid steady-state
plasma concentration of compound 2 on day-1 and cause
inhibition of H3K79 methylation in patients’ bone marrow
as well as peripheral blood cells. Eight patients out of 34
with an MLL-translocation showed biological or clinical
activity, among whom two complete responses as well as
one partial response were observed. More clinical trials in-
cluding combination therapies with other drugs are being
conducted.
DOT1L in other diseases
DOT1L has been identified to be a drug target for sev-
eral other types of cancers [78–80]. A bioinformatics
search found the expression levels of DOT1L correlate
with breast cancer as well as a panel of genes that pro-
mote proliferation of the malignancy [78]. Knockdown
of DOT1L and pharmacological inhibition (by e.g., com-
pound 1) showed inhibition of H3K79 methylation and
cell proliferation of several DOT1L+ breast cancer cell
lines with EC50 of 0.19–1.4 μM, while DOT1L
low breast
cancer cells were not sensitive to DOT1L inhibition.
Mechanistically, inhibition of DOT1L/H3K79 methylation
can impair self-renewal and metastatic potential, induce
differentiation and down-regulate many pro-proliferation
genes, all of which contribute to significantly reduced pro-
liferation of these breast cancer cells. H3K79 hypermethy-
lation was observed for lung cancer cell lines A549 and
NCI-H1299. siRNA-mediated DOT1L knockdown can
block the proliferation of these cells [79]. Therefore, these
experiments implied that DOT1L plays an important role
in lung cancer. However, no DOT1L inhibitors were
tested to confirm this finding. In addition to cancer,
DOT1L was recently found to play a role in cell repro-
gramming. DOT1L knockdown as well as compound 1
were shown to significantly increase the reprogramming
efficiency of somatic cells to produce more induced pluri-
potent stem cells (iPSC), showing the potential of using
DOT1L inhibitors in regenerative medicine [80].
MLL and LSD1 modifying H3K4 methylation
Cancer biology of MLL and LSD1
The biology of MLL has been extensively studies and
reviewed [52–54, 60–62] and briefly summarized in the
above section and here. The biological function of MLL
is essential for development: knockout of MLL in mice
is embryonic lethal. MLL has been found to associate
with thousands of gene promoters and have a global role
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in positive regulation of transcription of many important
genes such as Hox families of genes [81, 82]. Hox genes
are transcriptional factors essential for the development
of multiple tissues including the hematopoietic system,
while overexpression of certain members (e.g., HoxA9
etc.) has been found to lead to leukemogenesis [83].
MLL gene translocations are frequently found in acute
leukemia. Moreover, it is noted that MLL-translocation
occurs in one allele, with the wild-type (WT) MLL in
the other allele remaining intact. A recent study showed
that MLL’s H3K4 methyltransferase activity is essential
for MLL-rearranged leukemia, suggesting inhibition of
the SET domain of MLL is a possibly viable approach to
MLL leukemia treatment [84].
LSD1 plays an opposite role as a histone lysine
demethylase [22, 23]. LSD1 contains four functional
domains, including an N-terminal domain with a pu-
tative nuclear localization peptide, a SWIRM, and an
oxidase domain, inside which there is a tower domain
insert [85]. The last three domains are important for
demethylation. In addition, the tower domain, which
is not present in a closely related enzyme LSD2, dir-
ectly interacts with CoREST (also known as RCOR1,
repressor element-1 silencing transcription factor co-
repressor 1), through which LSD1 forms protein com-
plexes that regulate histone lysine methylation as well
as gene expression. The biological function of LSD1
is crucial, as germline LSD1 knockout in mice was
found to be embryonic lethal and conditional knock-
out caused increased H3K4me1/2, blocked
hematopoiesis and pancytopenia (low in all blood cell
types) [86]. The primary substrates of LSD1 are
H3K4me1 and me2, which are important histone
marks for active gene transcription. LSD1 was found
to be part of an MLL transcription complex [87]. A
possible function of LSD1 is to counteract MLL and
keep a balanced H3K4 methylation (Fig. 4a). Of inter-
est is that LSD1 has recently been found to be re-
quired for leukemia stem cells transformed with
MLL-AF9 [88]. LSD1 knockdown abrogated the trans-
forming ability of MLL-AF9, increased the H3K4me2
levels at MLL-AF9 target gene loci, and reduced the
expression of HoxA9 and Meis1. Presumably, LSD1
inhibition could counteract the loss of the SET do-
main in MLL-AF9 and restore a balanced H3K4
methylation. Pharmacological inhibition of LSD1
showed similar activities against MLL-AF9 leukemia
in vitro and in vivo [88]. Although there is a safety
concern of LSD1 inhibition [89, 90] because of LSD1’s
role in hematopoiesis [86, 91], a recent study showed
after termination of LSD1 conditional knockout the
impaired hematopoiesis can be recovered in a mouse
model [91]. These lines of evidence strongly support
that LSD1 is a drug target for MLL leukemia.
In addition, H3K9 and other proteins have been found
to be LSD1’s substrates [92–96]. In the context of andro-
gen receptor-mediated gene expression, histone H3
threonine 6 is phosphorylated by PKCβ1, which prevents
LSD1 from binding to methylated H3K4. In complex
with androgen receptor and PKCβ1, LSD1 can change its
substrate-specificity and demethylate H3K9me1 and 2
[92]. DNA methyltransferase 1 (DNMT1), which main-
tains the integrity of DNA methylation as well as plays an
important role in maintaining hematopoietic stem and
progenitor cells [97], is also a substrate of LSD1. DNMT1
is methylated in vivo and such methylation destabilizes
the protein. LSD1 can demethylate and therefore stabilize
DNMT1. Therefore, LSD1 is of importance in maintaining
global DNA methylation [93]. In addition, LSD1 can de-
methylate other non-histone proteins, such as p53 [94],
MYPT1 [95], and STAT3 [96], and regulate gene expres-
sion mediated by these proteins.
Overexpression of LSD1 has been found in many types
of cancer [98–102], including AML (without an MLL-
translocation), lung, breast, and prostate cancer. These
observations implicate that LSD1 is a potential drug tar-
get for these tumors. It was recently found that a signifi-
cant portion of cell lines of AML and small cell lung
cancer (SCLC) are highly sensitive to pharmacological
inhibition of LSD1 [103]. Although except for MLL-
rearranged leukemia, the molecular mechanisms that
link LSD1 to these malignancies are not fully understood
(likely because LSD1 has multiple protein substrates), in-
hibition of LSD1 generally caused broad gene expression
pattern changes in these sensitive tumors, which could be
responsible for the anti-proliferative activity and other ef-
fects, e.g., inducing apoptosis and/or differentiation.
LSD1 inhibitors and their biological activities
A number of small molecule inhibitors of LSD1 have
been discovered, developed, reported in the journals and
patents [103–112] and reviewed recently [16, 113].
These compounds can be classified into reversible and
irreversible inhibitors depending upon their modes of
action. We focus on the biological activities of the most
potent compounds. Figure 6 summarizes representative
inhibitors of these two classes, together with their en-
zyme and cellular activities. LSD1 belongs to a family of
monoamine oxidases (MAO), using FAD as the cofactor
for the redox reaction (Fig. 2a). The common feature for
irreversible LSD1 inhibitors is that upon oxidation, part
of the molecules is able to covalently bind to FAD and
permanently deactivates the enzyme [22]. However, for
reversible inhibitors, there is no covalent interaction be-
tween the inhibitor and the protein.
The first inhibitors of LSD1 with a common cyclopro-
pylamine core structure were derived from Tranylcypro-
mine (7, Fig. 6), an FDA-approved antidepression drug.
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Compound 7 is an inhibitor of MAO-A and -B, enzymes
that degrade neurotransmitters in the central nervous
system. Compound 7 weakly inhibits LSD1 with an IC50
of ~15 μM. More potent inhibitors have been developed
based on the structure of 7. Of importance for the in-
hibitor optimization is the introduction of a second
amine-containing N-substituent, such as those on the
right side of cyclopropylamine moiety in highly potent
LSD1 inhibitors 8–10. These basic groups not only
greatly increase the inhibitory activity, but also render
excellent LSD1 selectivity against MAO-A and -B [112].
Compound 8 (compound B in [88]) inhibited recombin-
ant LSD1 in vitro with an IC50 of 98 nM. It showed anti-
tumor activities against MLL-AF9 transformed leukemic
stem cells. It inhibited colony-forming ability of MLL-
AF9 containing leukemia cells with EC50 values as low
as 50 nM. It also down-regulated expression of many
leukemia-relevant genes such as HoxA7, HoxA9 and
Meis1. However, it exhibited somewhat severe toxicities
in a mouse model of MLL-AF9 leukemia, causing deaths
of many experimental mice presumably due to insuffi-
cient inhibitory potency and/or inappropriate dosages.
Compound 9 (compound 1 in [111]) is a much more po-
tent LSD1 inhibitor, almost quantitatively deactivating the
enzyme with an IC50 of 9.8 nM. It exhibited potent anti-
proliferative activity against MLL-rearranged leukemia cell
lines MV4-11 and Molm-13 with EC50 values of 10 and
96 nM, while 9 is almost inactive against leukemia cells
NB4 and U937 without an MLL-translocation. The differ-
ential activities of compound 9 (as well as several other
LSD1 inhibitors) suggest that the LSD1 inhibitor is non-
cytotoxic, but LSD1 is essential for MLL-rearranged
leukemia cells. In vivo antitumor studies using a systemic
murine model of MV4-11 leukemia showed that com-
pound 9 did not exhibit overt toxicities and was able to in-
hibit leukemia progression by >90 % and significantly
prolong survival of the experimental animals. Another po-
tent LSD1 inhibitor GSK2879552 (10) was found to ex-
hibit high anti-proliferative activity against 20 out of 29
AML cell lines with EC50 values ranging from ~3–100 nM
[103]. In addition, anti-proliferation screening of com-
pound 10 led to the finding that a significant portion (9
out of 28) of small cell lung carcinoma (SCLC) cell lines
were susceptible to 10 with EC50s of ~2–240 nM. This
compound also showed significant antitumor activity in a
mouse xenograft model of SCLC cancer. Similarly, com-
pound 10 is also devoid of general cytotoxicity: it did not
inhibit the growth of >100 cell lines across a range of can-
cer types, showing a high selectivity of using LSD1 inhibi-
tors targeting cancer. Mechanistic studies showed that
gene expression of TGF-β signaling, which is dysregulated
in SCLC, was significantly altered upon treatment with
compound 10. This could be attributed to the antitumor
activity of the LSD1 inhibitor. In addition, DNA hypome-
thylation of a gene set was identified to be correlated with
the sensitivity of SCLC cells (including primary patient
samples) to LSD1 inhibition [105]. This biomarker could
be used as a major criterion for patient recruitment. Com-
pound 10 has currently been in clinical trials for SCLC,
while no clinical data have been disclosed.
Several chemo-types of reversible LSD1 inhibitors have
been disclosed, among which compounds SP2509 (11)
[107], GSK690 (12) [16], and 13 (compound 17 in [112])
possess low nM in vitro inhibitory activity. Compound
11 potently inhibited LSD1 with an IC50 of 13 nM,
showing a non-competitive mode of action. Treatment
Fig. 6 Structures and activities of representative LSD1 inhibitors
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with 11 increased promoter-specific H3K4 methylation,
inhibited colony-formation, and induced differentiation
and apoptosis of several AML cell lines including MV4-
11, Molm-13, and OCI-AML3. The combination of 11
with an inhibitor of HDAC exhibited synergy and showed
significantly improved in vivo antileukemia activity in
mouse models of AML [107]. Compounds 12 and 13 are
quite similar, with the same 3-, 5-, 6-trisubstituted pyridine
core structure. Preliminary biological data of compound
12 were presented in the 2013 American Association of
Cancer Research annual meeting, showing 90 nM IC50
against LSD1, high enzyme selectivity, as well as low μM
cellular activity against AML cells. Compound 13 showed
an improved in vitro inhibitory activity (29 nM) against
LSD1 as well as good anti-proliferative activities (EC50:
0.36–3.6 μM) against several sensitive cancer cells includ-
ing MV4-11 with MLL-AF4 oncogene [112].
MLL inhibitors
In MLL-rearranged leukemia, the MLL gene transloca-
tion is heterozygous. The H3K4 methyltransferase activ-
ity of the remaining copy of WT MLL was found to be
essential for the malignancy [92]. Therefore, MLL inhibi-
tors could be useful to treat MLL-rearranged leukemia.
However, compounds that directly inhibit the SET do-
main of MLL have not been reported. Alternatively, the
MLL SET domain alone was found to have extremely
low methyltransferase activity [114, 115]. The optimal
enzyme activity requires its complexation with three
other proteins, i.e., WDR5, ASH2L, and RbBP5. Among
these, the interaction between WDR5 and MLL is crit-
ical, which led to the finding of indirect MLL inhibitors,
compounds that disrupt the binding of WDR5 to MLL
[116, 117]. Several compounds have recently been found
to bind to WDR5 with Kd values of <0.001–5.5 μM. To
date, the best compound MM-401 (14, Fig. 7), an ex-
tremely tight binder to WDR5 with a Kd value of <1 nM,
showed an IC50 of 0.9 nM in disrupting the interaction
between WDR5 and MLL. Indeed, compound 14 almost
quantitatively inhibited the methyltransferase activity of
the MLL complex (0.5 μM) with an IC50 value of
0.32 μM in vitro. Because the WDR5-MLL interaction is
unique, compound 14 exhibited a high enzyme selectiv-
ity profile: it did not inhibit several closely related SET
domain methyltransferases including MLL2 - 4, SET1,
and SET7/9. Consistent with MLL’s role, it showed se-
lective activity against MLL-rearranged leukemia cells.
Compound 14 inhibited the proliferation of MLL-
rearranged leukemia cells with EC50 values of 12–
30 μM, while it had no effects on other non-MLL
leukemia cells. The relatively weak cellular activity might
be due to the poor cell permeability of compound 14, a
cyclic peptidomimetic compound.
H3K27 methyltransferase EZH2
H3K27 methylation and EZH2 in health and cancer
SET domain containing EZH2 (Enhancer-of-zeste homo-
log 2) and its close homolog EZH1 catalyze mono-, di-
and tri-methylation of H3K27 [118–120]. EZH2 was
originally identified as a member protein of the Poly-
comb Repressive Complex 2 (PRC2), which functions as
a transcription repressor of Hox gene clusters important
to the development [121–123]. In 2002, it was further
determined to be a methyltransferase of H3K27 [118–
120]. EZH2 alone is not catalytically active. Complex-
ation with EED and SUZ12, two other members in
PRC2, is required to methylate H3K27 [124, 125]. The
biology of EZH2-containing PRC2 as well as their medi-
ated H3K27 methylation has been reviewed [121–123,
126]. Briefly, EZH2 is essential for embryonic develop-
ment and plays important roles in normal physiology.
EZH2 mediated H3K27me3 has been found to be a “his-
tone code” for transcription repression, while the genes
silenced by EZH2/H3K27me3 are different, depending
upon cell types [127]. Such epigenetic transcription re-
pression is essential to cell fate determination and func-
tion. However, the underlying regulatory mechanism for
the gene silencing is complicated and not fully under-
stood. Other proteins in the PRC2 complex also contrib-
ute to the gene silencing. For example, studies showed
that DNMT is associated with EZH2 in PRC2 and EZH2
is required to recruit DNMT to its target gene pro-
moters and methylate the DNA [128]. This finding
showed the two epigenetic events, i.e., H3K27me3 and
DNA methylation, are interconnected for transcription
repression. In addition, although the homologous EZH1
Fig. 7 Structure and activity of a compound that disrupts MLL:WDR5
interactions and thereby inhibits MLL indirectly
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also catalyzes H3K27 methylation as well as associates
with PRC2, it has different biological functions and can-
not substitute EZH2 [129].
Overexpression of EZH2 is often found in a variety of
cancers such as breast, prostate, lung and blood cancers
[130–135], with its expression level correlated with that
of H3K27me3, more virulent progression of the disease,
and poor prognosis. Further studies suggested that
EZH2 plays important roles in tumorigenesis, progres-
sion as well as metastasis [136, 137]. However, it remains
to be answered in these cases whether the methyltransfer-
ase activity of EZH2 is required for these cancers. Using
potent and selective EZH2 inhibitors, studies have re-
cently shown that proliferation of several types of cancer
cells was not significantly affected by pharmacological in-
hibition of EZH2/H3K27 methylation [78, 138, 139].
Recently, somatic mutations of EZH2 at Y641, and A677
were identified in 12–25 % non-Hodgkin lymphomas
[140–142]. Biochemical investigation revealed that these
EHZ2 mutants exhibit a different substrate-specificity from
that of the WT enzyme [143–145]. The WT EZH2 cata-
lyzes the mono-methylation of H3K27 with the highest
speed, while it is significantly less efficient for the second
and especially third methylation of H3K27. A reversed
trend was observed for the Y641 mutant proteins: they are
inactive for the first methylation, but these mutants trans-
fer the second and third methyl to H3K27 in an increasing
catalytic efficiency. In addition, the A677G mutant EZH2
can catalyze all three methylation at a high speed. Clinic-
ally, these EZH2 mutated lymphomas exhibit a particularly
high levels of H3K27me3.
EZH2 inhibitors
Recent high-throughput screening campaigns followed
by medicinal chemistry have identified several potent
and highly selective inhibitors of EZH2, as representa-
tively shown in Fig. 8. GSK126 (15) is the first disclosed
inhibitor with a Ki value of 0.5–3 nM against WT and all
mutant EZH2 enzymes [139]. It showed >150-fold
selectivity against EZH1 (Ki = 89 nM), as well as >1000-
fold selectivity against other HMTs. Enzyme kinetics stud-
ies suggested that compound 15 is competitive with the
enzyme cofactor SAM and non-competitive with the sub-
strate H3K27. It can potently inhibit cellular H3K27me3
levels with IC50 values of 7–252 nM in a broad variety of
cell lines, independent upon the status of EZH2 mutation.
Compound 15 was found to have strong anti-proliferative
activities (EC50 = 28–861 nM) against diffuse large B-cell
lymphoma cells containing an EZH2 activating mutation,
while lymphoma cells without an EZH2 mutation are gen-
erally insensitive. The antitumor activity has also been
confirmed in a mouse model study. Treatment with com-
pound 15 was able to cause the xenograft tumors to re-
gress in a dose-dependent manner and significantly
prolong the survivals of the tumor bearing mice. Mechan-
istically, treatment with compound 15 reduced the cellular
Fig. 8 Structures and activities of representative EZH2 inhibitors
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H3K27me3 levels and caused a broad range of transcrip-
tional activation of EZH2/PRC2 target genes in sensitive
lymphoma cells, while it did not significantly affect the
gene expression patterns of insensitive cells.
Scientists from several other institutes have also re-
ported their potent EZH2 inhibitors with enzyme IC50
values in the very low nM range [138, 146–149], as
shown representatively in Fig. 8. Most of these potent
EZH2 inhibitors contain the same or similar N-(2-pyridi-
none-3-yl)methyl amide substructure, suggesting this
moiety is important for protein binding. Enzyme kinetics
studies showed that these compounds exhibited a com-
petitive mode of action against the cofactor SAM, sug-
gesting that these compounds bind to the SAM-binding
site in EZH2. However, no X-ray structures of EZH2-
inhibitor complexes have been reported to date. The
exact binding modes of these compounds still need to
be explored, which could provide useful structural infor-
mation for further rational inhibitor design targeting
EZH2. Recently, EZH2 inhibitors 16 and CPI-1205 (with
an undisclosed structure) have entered clinical trials
against EZH2 mutated non-Hodgkin lymphomas, while
the results have not been disclosed.
Isocitrate dehydrogenase (IDH) mutation and
histone methylation
IDH mutation in glioma and other cancers
Isocitrate dehydrogenase (IDH) is one of the key en-
zymes in the tricarboxylic acid cycle for aerobic
metabolism of glucose [150]. There are three IDH iso-
zymes in humans, with IDH1 located in cytoplasm and
IDH2 and 3 in mitochondria [151]. Recent genetic stud-
ies have identified recurrent mutations of IDH in a num-
ber of cancers. IDH1 mutations were found in ~75 %
low-grade gliomas as well as secondary glioblastoma
multiforme (GBM), the grade IV glioma developed from
the low-grade tumors [152–156]. Of particular interest
is that all these mutations occur exclusively in the R132
residue of IDH1 or the corresponding R172 residue of
IDH2, with the R132H mutation being predominant
(>90 %) in these gliomas. Mutations of IDH1 or 2 have
also been found in ~20 % AML and several subtypes of
sarcomas [157–160]. The IDH mutations occur at an
early stage of these cancers, suggesting they could play
an important role in oncogenesis [161–163].
Biochemically, although mutant and WT IDH enzymes
do not directly work on histones, the products of their
catalyzed reactions are an inhibitor or cofactor of JmjC
domain histone demethylases (Fig. 2c) and therefore
affect histone lysine methylation. As shown in Fig. 9a,
WT IDH catalyzes the oxidative decarboxylation of iso-
citric acid to produce α-ketoglutaric acid (α-KG) [150],
while mutant IDH enzymes lose this function [164, 165].
Rather, all these mutants catalyze a new reaction, the
reduction of α-KG to D-2-hydroxyglutaric acid (D2HG)
(Fig. 9b) [157, 164, 166]. This new function generates
>100-fold elevated concentrations of D2HG in tumor
cells bearing an IDH1 or IDH2 mutation, while there is
only trace amount of D2HG in normal cells. The ex-
tremely high level of D2HG is therefore a hallmark of
IDH mutated glioma and is suggested to be used as a
biomarker for these types of cancers [157, 164, 166].
D2HG with its structure being very similar to α-KG has
been found to inhibit α-KG-dependent KDMs and TET
family of 5-methylcytosine hydroxylases [159, 167], which
are important enzymes to maintain a balanced methyla-
tion status of histone and DNA. IDH mutated cancers ex-
hibited genome-wide hypermethylation of histone and
DNA [159, 167–169]. In addition, transfection of IDH1
R132H mutation into U87 GBM cells without an IDH
mutation blocked cell differentiation and also caused
DNA/histone hypermethylation in a very similar fashion
to that observed in the clinical tumor samples [168, 170].
These lines of evidence strongly support IDH mutation is
a drug target for intervention.
Inhibitors of mutant IDH
Significant efforts from the academia and pharmaceut-
ical industry have been given to discover small molecule
inhibitors of mutant IDH. A number of potent and se-
lective inhibitors of mutant IDH1 and 2 with several
chemo-types have been published [171–177] and Fig. 9c
summarizes several representative compounds together
with their biological activities.
AGI-5198 (18) and AGI-6780 (19) with distinct chem-
ical structures were the first inhibitors of mutant IDH1
and IDH2, respectively [172, 173]. Dipeptide-like com-
pound 18 exhibited potent inhibitory activity against
IDH1 R132H (IC50 = 70 nM) and R132C (IC50 = 160 nM)
mutants, respectively, while it did not inhibit WT IDH1
or WT and mutant IDH2 enzymes (IC50 > 100 μM). This
compound can also reduce cellular D2HG concentrations
and the colony-forming ability of glioma cells with IDH1
R132H mutation. Because of the reduced cellular D2HG
as well as restored activity of histone demethylases, H3K9
methylation, a repressive histone mark, was found to be
decreased globally as well as in several gene promoters.
Compound 18 exhibited in vivo antitumor activity in a
mouse xenograft model of IDH1 mutated glioma. Com-
pound 19 is a urea-substituted benzenesulfamide com-
pound, showing selective activity against various mutant
forms of IDH2 with IC50 values of 4 – 170 nM, while it
exhibited high selectivity against WT IDH2 or IDH1 en-
zymes. It can similarly reduce cellular D2HG concentra-
tions effectively, inhibit proliferation and colony-forming
ability, and promote differentiation of primary AML cells
harboring an IDH2 mutation. Compounds 20–22 were re-
ported as potent and selective inhibitors of mutant IDH1,
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showing 0.013–0.42 μM inhibitory activities [174–177].
Compounds 21 and 22 can also selectively impair colony-
forming ability of patient derived glioma cells having
R132H IDH1 mutation.
AG-221 (23), an advanced inhibitor of mutant IDH2,
has been in phase I clinical trials against AML or myelo-
dysplastic syndrome with IDH2 mutations. Based on
data disclosed in the company’s press releases (www.
agios.com), compound 23 exhibited promising clinical
pharmacokinetic, safety and efficacy profiles. A total of
177 patients, who have relapsed or refractory AML with
IDH2 mutations, have been treated with various doses of
compound 23. The drug seems to be well tolerated, with
the majority of adverse effects being mild to moderate,
including nausea, fatigue, increased blood bilirubin and
diarrhea. The maximum tolerated dose of 23 has not
been reached. Preliminary pharmacokinetic and pharma-
codynamics studies showed compound 23 has an excel-
lent oral availability, and a high plasma half-life of >40 h.
Objective responses have been observed for 63 patients
out of 158 evaluable patients, showing an overall re-
sponse rate of 40 %. Among these, there were 26 cases
of complete remission (CR), three cases of CR with in-
complete platelet recovery, 14 cases of marrow CR, two
cases of CR with incomplete hematological recovery as
well as 18 cases of partial remission. Given these prom-
ising clinical data, more clinical evaluations of com-
pound 23 as well as several other inhibitors of mutant
IDH are currently on-going worldwide.
Inhibitors of selected other histone methylation
enzymes
There are excellent review articles that summarize the
biology of HKMTs, PRMTs and KDMs as well as their
relevance to cancer or other diseases [4, 8, 15–17, 178].
As compared to the large number (>100) of these histone
methylation enzymes, relatively fewer number of potent
and selective small molecule inhibitors have been discov-
ered in the past few years. We describe below potent in-
hibitors of several other important histone methylation
modifying enzymes (Fig. 10). Most of these compounds
are cell permeable and can be used as chemical probes for
biological studies of these proteins. However, a number
of previously reported inhibitors are not included, be-
cause of low potency (e.g., with μM enzyme IC50s),
non-specificity, or unknown mechanism of action. It is
therefore unclear whether the observed biological
Fig. 9 Mechanisms and inhibitors of IDH. a Mechanism of catalysis for the wild-type IDH. b Mechanism of catalysis for mutant IDHs. c Structures
and activities of representative inhibitors of mutant IDH
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activities of these compounds are due to inhibition of
the protein target or off-target effects.
Inhibitors of other HKMTs
G9a (also known as EHMT2) and its closely homologous
protein GLP (also known as EHMT1) are responsible for
mono- and di-methylation of H3K9 [179] and play im-
portant roles in gene regulation. There is also strong evi-
dence that G9a/GLP is implicated in several types of
cancers [180–182]. The first specific inhibitor of G9a is
BIX-01294 (24, Fig. 10a) identified in a high-throughput
screening [183]. Compound 24 exhibits an IC50 of 180
nM against G9α, whereas no inhibition of the other his-
tone methyltransferases, such as SUV39H1 and PRMT1,
was observed. In a cellular assay, 24 was found to transi-
ently modulate H3K9me2 marks. Medicinal chemistry
modifications based on the scaffold of 24 yielded a series
of compounds with improved potency as well as cell per-
meability, such as UNC0224 (25) [21] and UNC0638
(26) [184]. Compound 25 exhibited an improved IC50 of
43 nM against G9α by adding a lysine mimetic group.
An X-ray crystal structure of G9a in complex with 25 re-
vealed that this group occupies the lysine binding channel
of the protein. Compound 26 is a potent, selective and cell
permeable G9a inhibitor, able to reduce H3K9me2 levels
in a dose-dependent manner with an EC50 of 81 nM. Fur-
thermore, compound 26 can reduce colony-forming abil-
ity of breast cancer MCF-7 and MDA-MB231 cells.
Compound A-366 (27) with a distinct chemo-type is also
a highly potent and selective inhibitor of G9a with an IC50
of 3.3 nM [185].
SMYD2 is a SET domain-containing methyltransferase
with a less restricted substrate-specificity. H3K4 and
H3K36 as well as non-histone proteins such as HSP90
Fig. 10 Structures and activities of representative inhibitors of a G9a/GLP; b SMYD2; c PRMTs; and d KDM6
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and p53 were found to be a substrate of SMYD2. Be-
cause of the observed overexpression in a variety of can-
cer types [186, 187], it is implicated as a drug target.
The first SMYD2 specific inhibitor AZ505 (28, Fig. 10b)
was identified in a high-throughput screening, showing
an enzyme IC50 of 120 nM as well as selectivity indices
of >690-fold [188]. The steady-state kinetic studies indi-
cated that this compound is competitive to the peptide
substrate and uncompetitive for the cofactor SAM,
which was confirmed by an X-ray crystallographic inves-
tigation of the SMYD2-28 complex. LLY-507 (29) was
disclosed to be a more potent inhibitor of SMYD2 (IC50
< 15 nM), together with >100-fold selectivity over other
KMTs [189]. Compound 29 inhibited cellular methyla-
tion with an EC50 of ~600 nM, showing it is a good
chemical probe for investigation of the functions of
SMYD2 in normal physiology and diseases.
Inhibitors of PRMTs
There are two types of PRMTs [9]. The majority of
PRMTs (including PRMT1-4, 6, and 8) are the type I en-
zymes, catalyzing mono- and asymmetric di-methylation
of an arginine sidechain. PRMT5 is the only known type
II enzyme, catalyzing symmetric di-methylation of an
arginine.
CMPD-1 (30, Fig. 10c) is a potent inhibitor of PRMT4
(also known as CARM1) with an enzyme IC50 of 30 nM
as well as selectivity indices of >300-fold against PRMT1
and 3 [190]. X-ray crystallography showed that com-
pound 30 occupies the substrate-binding pocket and the
high selectivity arises from sequence differences between
PRMT4 and PRMT1/3.
An allosteric inhibitor SGC707 (31) is a highly potent
inhibitor of PRMT3 an IC50 of 31 nM [191]. It exhibited
no inhibitory activity against a panel of 27 protein meth-
yltransferases. Crystallographic studies of the PRMT3-31
complex revealed that the inhibitor occupies a cavity
>15 Å from the enzyme active site. In cellular assay,
compound 31 was able to reduce H4R3me2 with an
EC50 of 225 nM.
EPZ020411 (32) has been reported to inhibit PRMT6
with an IC50 of 10 nM, while it exhibited good selectivity
(>10 fold) against PRMT1 and 8 [192]. In cellular assays,
treatment with 32 resulted in a dose-dependent decrease
of H3R2me2 with an EC50 of 640 nM.
Besides the above selective inhibitors against an indi-
vidual PRMT enzyme, it is of interest that MS023 (33) is
a pan-inhibitor of type I PRMTs [193]. It was designed
based on the structures of PRMT4 inhibitor 30 and
PRMT6 inhibitor 32. Compound 33 exhibited an en-
zyme IC50 of 30, 119, 83, 4, and 5 nM against PRMT1,
3, 4, 6, and 8, respectively. Treatment with 33 signifi-
cantly decreased levels of H3R2me2 and H4R3me2 with
EC50s of 56 and 9 nM, respectively.
EPZ015666 (34) was reported as a potent and selective
inhibitor of PRMT5 (IC50 = 22 nM), a type II PRMT [194].
Compound 34 demonstrated potent anti-proliferative ac-
tivity against mantle cell lymphoma cells Z-138 and
Maver-1 (EC50 = 96 and 450 nM, respectively), because of
overexpression of PRMT5 in this type of tumor. It also
showed in vivo antitumor activity in xenograft mouse
models of these two lymphoma cells.
Inhibitors of other KDMs
Despite a number of compounds were reported to be in-
hibitors of the JmjC family of KDMs, they are either an-
alogs of α-KG or metal chelators (e.g., hydroxamates and
pyridinyl carboxylates) [16]. These compounds generally
lack potent inhibitory activity (mostly having μM IC50s)
and enzyme selectivity. In addition, cellular activities,
such as histone methylation changes, anti-proliferation
and/or toxicity, of these compounds have not been well
investigated. Recently, GSK-J1 (35) was reported to be a
selective inhibitor of KDM6, responsible for demethyla-
tion of H3K27. Compound 35 was initially identified as a
lead in a high-throughput, fluorescence based AlphaSc-
reen assay and later confirmed to selectively inhibit
KDM6B with an IC50 of 5 μM, while it exhibited ~10-fold
selectivity against KDM4 enzymes [195]. X-ray crystallog-
raphy showed 35 binds to the active site of the protein
with two of its N atoms chelating the metal ion. Com-
pound 35 is not cell permeable, while its ester prodrug
GSK-J4 was found to inhibit cellular production of TNF-α
with an EC50 of 9 μM. While the global histone methyla-
tion changes were not determined, GSK-J4 inhibited a
reduction of the H3K27me3 level at the TNFA gene pro-
moter using chromatin immunoprecipitation (ChIP) as-
says, suggesting it is on-target in cells.
Perspectives and conclusions
Histone methylation plays critical roles in gene regula-
tion, cell differentiation, DNA recombination and dam-
age repair. Histone methylation modifying enzymes,
which are often part of a transcription complex, have
been heavily studied for the past few decades and great
amount of understanding has been obtained for their
biochemistry, structures and biological functions in nor-
mal physiology as well as in pathogenesis. Many of these
enzymes have been validated or implicated as drug tar-
gets for intervention. Small molecule inhibitors of these
proteins are not only potential therapeutics, but also
useful chemical probes for investigation of biological
functions of histone modifying enzymes. To date, dis-
covery and development of small molecule inhibitors of
HMTs and KDMs have been still in a very early stage,
with significant efforts and successful stories from the
academia and pharmaceutical industry occurring only in
the past few years. However, it is exciting that the field
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has been growing exponentially: as described in this re-
view, highly potent and selective inhibitors of several
such proteins, including DOT1L, LSD1, EZH2, and mu-
tant IDH, have been developed and undergone extensive
preclinical testing. Several compounds have quickly en-
tered and been evaluated in clinical trials in just a few
years. They have demonstrated promising clinical safety
and efficacy, showing great potentials to become clinic-
ally useful drugs. These remarkable outcomes could fur-
ther attract more scientists to the field and jump-start
drug discovery and development endeavors targeting
histone methylation for cancer therapy. However, due to
important functions of histone methylation in normal
physiology, inhibition of histone methylation enzymes
could cause toxicities. Vigorous toxicological studies
should be performed to ensure there is a sufficient
therapeutic window for such pharmacological inhibition.
Additionally, small molecule compounds targeting his-
tone methylation enzymes could provide great oppor-
tunities for finding new cancer biology. Given the
differences between pharmacological inhibition and gen-
etic knockdown, using these compounds as probes can
complement biological means to explore the functions
of a histone methylation protein in health and diseases.
For example, many of these proteins (e.g., MLL and
DOT1L) contains multiple domains having more func-
tions than being a methyltransferase. Pharmacological
inhibition of the catalytic domain of the protein, without
disturbing the functions of other domains, could provide
more useful insight. Moreover, in the context of cancer
therapy, overexpression of a certain histone methylation
protein is often found in cancer. However, it is still un-
clear whether the cancer is dependent upon the catalytic
activity of such protein. These compounds can be used
to validate whether the protein is a real drug target.
Many of the inhibitors shown in Figs. 4, 5, 6, 7, 8, 9, and
10 are commercially available for these studies. The
availability and costs can be found in PubChem (https://
pubchem.ncbi.nlm.nih.gov/).
There are still a number of challenges in the field from
the perspectives of chemistry and biology. From the chem-
istry side, finding potent and selective small molecule in-
hibitors is a major challenge, because these enzymes share
a relatively high homology and use the same cofactor. This
requires an enormous amount of coordinated efforts in
high-throughput screening, ligand and structure-based in-
hibitor design and synthesis, medicinal chemistry as well
as biological activity testing. If successful, this is, however,
the first step towards yielding a clinically useful drug. Re-
peated rounds of medicinal chemistry, in vitro and in vivo
pharmacokinetics, toxicity and efficacy testing are needed
to find suitable drug candidates, which is followed by a
low success rate in clinical trials. Very high costs for the
whole process represent another barrier. From the biology
side, more studies need to be performed to validate
whether a histone modifying enzyme is a cancer target.
Because of the high costs for high-throughput screening
and medicinal chemistry, it is desirable that sufficient evi-
dence showing a critical function of the enzyme has been
found in the disease before compound development. Gen-
etic screening of gene mutations in clinical tumor samples
represents a powerful means to identify potential candi-
dates (e.g., work in 5.1 and 6.1 for mutations of EZH2 and
IDH and [196]). Ensuing biochemical and biological stud-
ies are needed to further identify the links between the
functions of such mutation and pathogenesis. In addition,
determination and comparative analysis of methylation
levels at different histone residues (e.g., H3K79me2 in
[67]) between normal and patient samples could provide
useful hints. If there are available resources, direct screen-
ing a collection of specific inhibitors of histone modifying
enzymes against a large number of cancer cell lines is also
a fruitful measure to find such links (e.g., work in [103]).
With the successful stories summarized here, it is envi-
sioned that more histone methylation enzymes can be
identified as therapeutic targets for cancer.
Combination therapy is a viable approach to increase the
effectiveness of a histone methylation modulator. Because
multiple histone modifications that change global gene ex-
pression might be involved in a certain type of cancer,
combination therapy targeting two or more closely associ-
ated epigenetic changes could be synergistic. For example,
strong synergy was observed for combination treatment
using inhibitors of LSD1 and DOT1L that closely associ-
ated in MLL-rearranged leukemia [111]. Synergy was also
found for combination therapy of a LSD1 inhibitor with an
HDAC inhibitor in vitro and in AML mouse models [107].
Aberrant methylation of DNA and histone are often asso-
ciated [197–199], combination with a DNA methylation
inhibitor could also be useful. To rationally design a syner-
gistic combination therapy, mechanistic studies of onco-
genesis at the molecular level are helpful to find two
possible candidate proteins for intervention [200]. In
addition, combination therapy is useful to overcome drug
resistance as well as reduce toxicities and side effects.
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